Relationships Between the Achieved Target Levels of LDL Cholesterol and the State of Various Types of LV EF in Patients with Coronary Artery Disease and Type 2 Diabetes

Today, diabetes mellitus is one of the most powerful risk factors for the development of cardiovascular diseases and its complications. [1] In 50% of patients with type 1 diabetes and in 80% of people with type 2 diabetes, early disability and premature death are recorded due to cardiovascular complications. People with diabetes are often at risk for strokes, heart attacks, and high blood pressure. In this regard, the main strategy for the treatment of patients with diabetes is to prevent the development of cardiovascular complications, which includes strict control of glycemia, blood pressure, as well as antiplatelet and lipid-lowering therapy.

Despite the fact that strict glycemic control alone does not reduce the risk of myocardial infarction and mortality from it, most epidemiological and pathophysiological studies indicate a worse prognosis and a higher incidence of cardiovascular complications in chronic hyperglycemia. The use of a fixed combination of sitagliptin / metformin is one of the preferred options in the treatment of type 2 diabetes in patients with a high risk of cardiovascular disease due to the presence of type 4 dipeptidyl peptidase inhibitors of cardio protective effects. In this paper, changes in the lipid spectrum in patients with ischemic heart disease and type 2 diabetes mellitus with varying degrees of cardiac output are related to the number of years the patient has had diabetes mellitus, sitagliptin / metformin and statin drugs changes depending on the dose are highlighted.